ClinicalTrials.gg
CompletedNCT01721044RA-BEACONUpdated Sep 18, 2019Results posted

A Moderate to Severe Rheumatoid Arthritis Study

A Phase 3 interventional study of Placebo and Baricitinib in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 103 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
527
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.

Enrollment
8th of 23
527 · median 290
Started
2013
with 1 other
Phase 3
8 of 23
1 open now
Registered
7th of 23
by date
Lead sponsor
11 of 23
Eli Lilly and Company

Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 8th largest by enrollment, is one of 2 that started in 2013, is one of 8 in phase 3, and was the 7th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing baricitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to a tumor necrosis factor (TNF) inhibitor, despite ongoing treatment with conventional disease-modifying antirheumatic drugs (cDMARDs).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) as defined by the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2010 Criteria for the Classification of RA
  • Have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints
  • Have a C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement ≥ (greater than or equal to) 1 times the (ULN)
  • Have been treated at approved doses with at least 1 biologic tumor necrosis factor (TNF)- alpha inhibitor for at least 3 months and either:

    • experienced insufficient efficacy or loss of efficacy
    • experienced intolerance of such treatment
  • Have had regular use of at least 1 conventional disease-modifying antirheumatic drugs (cDMARD) for at least the 12 weeks prior to study entry with a continuous, nonchanging dose for at least 8 weeks prior to study entry

Exclusion criteria

Exclusion Criteria:

  • Have received a biologic treatment for RA within 28 days of planned randomization; have received rituximab within 6 months of planned randomization
  • Are currently receiving at doses > (greater than) 10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization
  • Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization
  • Are currently receiving concomitant treatment with methotrexate (MTX), hydroxychloroquine, and sulfasalazine or combination of any 3 cDMARDs
  • Have received any parenteral corticosteroid administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study
  • Have had 3 or more joints injected with intraarticular corticosteroids or hyaluronic acid within 2 weeks prior to study entry or within 6 weeks prior to planned randomization
  • Have active fibromyalgia that, in the investigator's opinion, would make it difficult to appropriately assess RA activity for the purposes of this study
  • Have a diagnosis of any systemic inflammatory condition other than RA, such as, but not limited to juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, active vasculitis or gout (participants with secondary Sjogren's syndrome are not excluded.)
  • Have a diagnosis of Felty's syndrome
  • Have had any major surgery within 8 weeks of study entry or will require major surgery during the study that, in the opinion of the investigator in consultation with Lilly or its designee, would pose an unacceptable risk to the participant
  • Have experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or have stage IV heart failure
  • Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking product or could interfere with the interpretation of data
  • Are largely or wholly incapacitated permitting little or no self care, such as, being bedridden or confined to a wheelchair
  • Have an estimated (eGFR) based on the most recent available serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of \< (less than) 40 milliliter per minute per 1.73 m\^2 (mL/min/1.73 m\^2)
  • Have a history of chronic liver disease with the most recent available (AST) or alanine aminotransferase (ALT) >1.5 times the or the most recent available total ≥1.5 times the ULN
  • Have a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from for \<5 years
  • Have been exposed to a within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)
  • Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection
  • Have had symptomatic herpes zoster infection within 12 weeks prior to study entry
  • Have a history of disseminated/complicated herpes zoster (eg, multidermatomal involvement, ophthalmic zoster, central nervous system involvement, postherpetic neuralgia)
  • Are and, in the opinion of the investigator, are at an unacceptable risk for participating in the study
  • Have a history of active virus (HBV), virus (HCV), or (HIV)
  • Have screening laboratory test values, including thyroid-stimulating hormone (TSH), outside the reference range for the population or investigative site that, in the opinion of the investigator, pose an unacceptable risk for the participant's participation in the study
  • Have screening (ECG) abnormalities that, in the opinion of the investigator or the sponsor, are clinically significant and indicate an unacceptable risk for the participant's participation in the study (e.g. Fridericia's interval >500 millisecond [msec])
  • Have symptomatic herpes simplex at the time of study enrollment
  • Have evidence of active or latent tuberculosis (TB)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
527 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24. Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.

    Drug: Placebo · Drug: cDMARD

  • Experimental
    Baricitinib 2 mg

    Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24. Participants will continue to take background cDMARD therapy throughout study.

    Drug: Baricitinib · Drug: cDMARD

  • Experimental
    Baricitinib 4 mg

    Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24. Participants will continue to take background cDMARD therapy throughout study.

    Drug: Baricitinib · Drug: cDMARD

Interventions

  • DrugPlacebo

    Administered orally

  • Administered orally

    Also known as: LY 3009104, INCB 028050

  • DrugcDMARD

    Participants will continue to take background cDMARD therapy throughout study.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response - Placebo Versus Baricitinib 4 mg

    ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis. ACR20 Responder is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity using visual analog scale (VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI), pain due to arthritis, and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and participants who discontinue study or drug or are rescued before analysis timepoint are deemed non-responders.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in HAQ-DI Score - Placebo Versus Baricitinib 4 mg

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

    Time frame: Baseline, Week 12

  2. Change From Baseline in the Disease Activity Score Based on a 28-Joint Count (DAS-28) High Sensitivity C-Reactive Protein (hsCRP) - Placebo Versus Baricitinib 4 mg

    DAS-28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), high sensitivity C-reactive protein (hsCRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-hsCRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

    Time frame: Baseline, Week 12

  3. Percentage of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Remission - Simplified Disease Activity Index (SDAI) ≤3.3 - Placebo Versus Baricitinib 4 mg

    The ACR/EULAR definitions of rheumatoid arthritis (RA) remission includes an index-based definition. The index-based definition of remission occurs with a SDAI score ≤3.3. The SDAI is a tool for measurement of disease activity in RA that integrates TJC28 (0 to 28), SJC28 (0 to 28), acute phase response using C-reactive protein (0.1 to 10.0 mg/dL), Patient's Global Assessment of Disease Activity using VAS (0 to 10.0 cm), and Physician's Global Assessment of Disease Activity using VAS (0 to 10.0 cm). Lower scores indicated less disease activity.

    Time frame: Week 12

  4. Percentage of Participants Achieving ACR20 Response - Placebo Versus Baricitinib 2 mg

    ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis. ACR20 Responder is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity using VAS, Patient's Global Assessment of Disease Activity using VAS, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.

    Time frame: Week 12

  5. Change From Baseline in HAQ-DI Score - Placebo Versus Baricitinib 2 mg

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate the HAQ-DI score. Total scores ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

    Time frame: Baseline, Week 12

  6. Change From Baseline in the DAS28 - hsCRP - Placebo Versus Baricitinib 2 mg

    DAS28 consisted of composite score of following variables: TJC28, SJC28, hsCRP (mg/mL), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

    Time frame: Baseline, Week 12

  7. Percentage of Participants Achieving ACR/EULAR Remission - SDAI ≤3.3 - Placebo Versus Baricitinib 2 mg

    The ACR/EULAR definitions of rheumatoid arthritis (RA) remission includes an index-based definition. The index-based definition of remission occurs with a SDAI score ≤3.3. The SDAI is a tool for measurement of disease activity in RA that integrates TJC28 (0 to 28), SJC28 (0 to 28), acute phase response using C-reactive protein (0.1 to 10.0 mg/dL), Patient's Global Assessment of Disease Activity using VAS (0 to 10.0 cm), and Physician's Global Assessment of Disease Activity using VAS (0 to 10.0 cm). Lower scores indicated less disease activity.

    Time frame: Week 12

  8. Percentage of Participants Achieving ACR20 Response

    ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis. ACR20 Responder is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity using VAS, Patient's Global Assessment of Disease Activity using VAS, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.

    Time frame: Week 24

  9. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response

    ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. ACR50 Responder is a participant who has at least 50% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.

    Time frame: Week 12 and Week 24

  10. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response

    ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. ACR70 Responder is a participant who has at least 70% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.

    Time frame: Week 12 and Week 24

  11. Change From Baseline in DAS28 - Erythrocyte Sedimentation Rate (ESR)

    DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

    Time frame: Baseline, Week 12

  12. Change From Baseline in Clinical Disease Activity Index Score

    The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

    Time frame: Baseline, Week 24

  13. Change From Baseline in Measures of SDAI Score

    The SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 24

  14. Percentage of Participants Achieving ACR/EULAR Remission - Boolean Remission

    The ACR/EULAR definitions of RA remission includes a Boolean-based definition. The Boolean-based definition of remission occurs when all 4 of the following criteria are met at the same visit: TJC28 ≤1, SJC28 ≤1, acute phase response using C-reactive protein (milligrams per deciliter) ≤1, Patient's Global Assessment of Disease Activity using VAS (cm) ≤1.

    Time frame: Week 24

  15. Change From Baseline in Duration of Participant Reported Outcome - Morning Joint Stiffness

    Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on that day. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

    Time frame: Baseline, Week 24

  16. Change From Baseline in Worst Tiredness Numeric Rating Scale (NRS)

    A participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing (no tiredness) and 10 representing (as bad as you can imagine). Participants rate their tiredness by selecting the one number that describes their worst level of tiredness during the past 24 hours. Total scores ranged from 0-10.

    Time frame: Baseline, Week 24

  17. Change From Baseline in Worst Joint Pain NRS

    Participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing (no joint pain) and 10 representing (pain as bad as you can imagine). Participants rate their joint pain by selecting the one number that describes their worst level of joint pain during the past 24 hours. Total scores ranged from 0-10.

    Time frame: Baseline, Week 24

  18. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale Scores

    The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 (Not at all) to 4 (Very much) for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.

    Time frame: Baseline, Week 12, Week 24

  19. Change From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)

    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status.

    Time frame: Baseline, Week 12, Week 24

  20. Change From Baseline in European Quality of Life-5 Dimensions-5 Level Scores

    European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.

    Time frame: Baseline, Week 12, Week 24

  21. Percentage Change From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Scores

    The WPAI-RA participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. Using 6 questions, it yields four types of scores: absenteeism (work time missed), presenteeism (impairment at work), work productivity loss (overall work impairment), and activity impairment, with outcomes expressed as impairment percentages. Percentage work time missed absenteeism: Q2/(Q2+Q4)\*100, Percentage impairment while working presenteeism: Q5/10\*100; Percentage overall work impairment work productivity loss: Q2/(Q2+Q4)+\[(1-Q2/(Q2+Q4))x(Q5/10)\]\*100; Percentage activity impairment activity impairment: Q6/10\*100. Higher numbers indicate greater impairment and less productivity, that is, worse outcomes.

    Time frame: Baseline, Week 12, Week 24

  22. Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib

    Time frame: Week 0 (Baseline): 15 min. post-dose, 1 hour post-dose. Week 4 (Day 28 ±2 days): 2 to 4 hours post-dose. Week 8 (Day 56 ±3 days): 4 to 6 hours post-dose. Week 12 (Day 84 ±3 days): Pre-dose. Week 24 (Day 168 ±5 days): Pre-dose.

  23. Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib

    Time frame: Week 0 (Baseline): 15 min. post-dose, 1 hour post-dose. Week 4 (Day 28 ±2 days): 2 to 4 hours post-dose. Week 8 (Day 56 ±3 days): 4 to 6 hours post-dose. Week 12 (Day 84 ±3 days): Pre-dose. Week 24 (Day 168 ±5 days): Pre-dose.

07

Results

Posted Jan 18, 2018

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestonePlaceboBaricitinib 2 mgBaricitinib 4 mg
Started176174177
Rescue week 16-24563833
Completed144157158
Not completed321719
Withdrew: Adverse event7710
Withdrew: Death001
Withdrew: Lack of efficacy1644
Withdrew: Lost to follow-up001
Withdrew: Physician decision102
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject761
Follow Up
Participant flow — Follow Up
MilestonePlaceboBaricitinib 2 mgBaricitinib 4 mg
Started19920
Completed19920
Not completed000

Outcome measures

PrimaryPercentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response - Placebo Versus Baricitinib 4 mg

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis. ACR20 Responder is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity using visual analog scale (VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI), pain due to arthritis, and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and participants who discontinue study or drug or are rescued before analysis timepoint are deemed non-responders.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response - Placebo Versus Baricitinib 4 mg
Percentage of ParticipantsPlaceboBaricitinib 4 mg
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response - Placebo Versus Baricitinib 4 mg27.355.4
Statistical analysis
  • Placebo vs Baricitinib 4 mg · Regression, Logistic · p = 0.001If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
SecondaryChange From Baseline in HAQ-DI Score - Placebo Versus Baricitinib 4 mg

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

Time frame:
Baseline, Week 12
Reported as:
Mean · Units on a Scale
Change From Baseline in HAQ-DI Score - Placebo Versus Baricitinib 4 mg
Units on a ScalePlaceboBaricitinib 4 mg
Change From Baseline in HAQ-DI Score - Placebo Versus Baricitinib 4 mg-0.20 ± 0.50-0.42 ± 0.49
Statistical analysis
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001
SecondaryChange From Baseline in the Disease Activity Score Based on a 28-Joint Count (DAS-28) High Sensitivity C-Reactive Protein (hsCRP) - Placebo Versus Baricitinib 4 mg

DAS-28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), high sensitivity C-reactive protein (hsCRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-hsCRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

Time frame:
Baseline, Week 12
Reported as:
Mean · Units on a Scale
Change From Baseline in the Disease Activity Score Based on a 28-Joint Count (DAS-28) High Sensitivity C-Reactive Protein (hsCRP) - Placebo Versus Baricitinib 4 mg
Units on a ScalePlaceboBaricitinib 4 mg
Change From Baseline in the Disease Activity Score Based on a 28-Joint Count (DAS-28) High Sensitivity C-Reactive Protein (hsCRP) - Placebo Versus Baricitinib 4 mg-0.85 ± 1.19-1.81 ± 1.43
Statistical analysis
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001
SecondaryPercentage of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Remission - Simplified Disease Activity Index (SDAI) ≤3.3 - Placebo Versus Baricitinib 4 mg

The ACR/EULAR definitions of rheumatoid arthritis (RA) remission includes an index-based definition. The index-based definition of remission occurs with a SDAI score ≤3.3. The SDAI is a tool for measurement of disease activity in RA that integrates TJC28 (0 to 28), SJC28 (0 to 28), acute phase response using C-reactive protein (0.1 to 10.0 mg/dL), Patient's Global Assessment of Disease Activity using VAS (0 to 10.0 cm), and Physician's Global Assessment of Disease Activity using VAS (0 to 10.0 cm). Lower scores indicated less disease activity.

Time frame:
Week 12
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Remission - Simplified Disease Activity Index (SDAI) ≤3.3 - Placebo Versus Baricitinib 4 mg
Percent of ParticipantsPlaceboBaricitinib 4 mg
Percentage of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Remission - Simplified Disease Activity Index (SDAI) ≤3.3 - Placebo Versus Baricitinib 4 mg1.75.1
Statistical analysis
  • Placebo vs Baricitinib 4 mg · Regression, Logistic · p = 0.140If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
SecondaryPercentage of Participants Achieving ACR20 Response - Placebo Versus Baricitinib 2 mg

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis. ACR20 Responder is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity using VAS, Patient's Global Assessment of Disease Activity using VAS, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ACR20 Response - Placebo Versus Baricitinib 2 mg
Percentage of ParticipantsPlaceboBaricitinib 2 mg
Percentage of Participants Achieving ACR20 Response - Placebo Versus Baricitinib 2 mg27.348.9
Statistical analysis
  • Placebo vs Baricitinib 2 mg · Regression, Logistic · p = 0.001If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
SecondaryChange From Baseline in HAQ-DI Score - Placebo Versus Baricitinib 2 mg

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate the HAQ-DI score. Total scores ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

Time frame:
Baseline, Week 12
Reported as:
Mean · Units on a Scale
Change From Baseline in HAQ-DI Score - Placebo Versus Baricitinib 2 mg
Units on a ScalePlaceboBaricitinib 2 mg
Change From Baseline in HAQ-DI Score - Placebo Versus Baricitinib 2 mg-0.20 ± 0.50-0.38 ± 0.51
Statistical analysis
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.001
SecondaryChange From Baseline in the DAS28 - hsCRP - Placebo Versus Baricitinib 2 mg

DAS28 consisted of composite score of following variables: TJC28, SJC28, hsCRP (mg/mL), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

Time frame:
Baseline, Week 12
Reported as:
Mean · Units on a Scale
Change From Baseline in the DAS28 - hsCRP - Placebo Versus Baricitinib 2 mg
Units on a ScalePlaceboBaricitinib 2 mg
Change From Baseline in the DAS28 - hsCRP - Placebo Versus Baricitinib 2 mg-0.85 ± 1.19-1.53 ± 1.34
Statistical analysis
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.001
SecondaryPercentage of Participants Achieving ACR/EULAR Remission - SDAI ≤3.3 - Placebo Versus Baricitinib 2 mg

The ACR/EULAR definitions of rheumatoid arthritis (RA) remission includes an index-based definition. The index-based definition of remission occurs with a SDAI score ≤3.3. The SDAI is a tool for measurement of disease activity in RA that integrates TJC28 (0 to 28), SJC28 (0 to 28), acute phase response using C-reactive protein (0.1 to 10.0 mg/dL), Patient's Global Assessment of Disease Activity using VAS (0 to 10.0 cm), and Physician's Global Assessment of Disease Activity using VAS (0 to 10.0 cm). Lower scores indicated less disease activity.

Time frame:
Week 12
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving ACR/EULAR Remission - SDAI ≤3.3 - Placebo Versus Baricitinib 2 mg
Percent of ParticipantsPlaceboBaricitinib 2 mg
Percentage of Participants Achieving ACR/EULAR Remission - SDAI ≤3.3 - Placebo Versus Baricitinib 2 mg1.72.3
Statistical analysis
  • Placebo vs Baricitinib 2 mg · Regression, Logistic · p = 0.723If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
SecondaryPercentage of Participants Achieving ACR20 Response

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis. ACR20 Responder is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity using VAS, Patient's Global Assessment of Disease Activity using VAS, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ACR20 Response
Percentage of ParticipantsPlaceboBaricitinib 2 mgBaricitinib 4 mg
Percentage of Participants Achieving ACR20 Response27.344.846.3
Statistical analysis
  • Placebo vs Baricitinib 4 mg · Regression, Logistic · p = 0.001 (a priori p-value significance threshold: 2-sided \<=0.05)If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
  • Placebo vs Baricitinib 2 mg · Regression, Logistic · p = 0.001 (a priori p-value significance threshold: 2-sided \<=0.05)If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
SecondaryPercentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response

ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. ACR50 Responder is a participant who has at least 50% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.

Time frame:
Week 12 and Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response
Percentage of ParticipantsPlaceboBaricitinib 2 mgBaricitinib 4 mg
Week 128.020.128.2
Week 2413.123.029.4
Statistical analysis
  • Placebo vs Baricitinib 4 mg · Regression, Logistic · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
  • Placebo vs Baricitinib 2 mg · Regression, Logistic · p = 0.002 (a priori p-value significance threshold: 2-sided ≤0.05)If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
  • Placebo vs Baricitinib 4 mg · Regression, Logistic · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
  • Placebo vs Baricitinib 2 mg · Regression, Logistic · p = 0.015 (a priori p-value significance threshold: 2-sided ≤0.05)If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
SecondaryPercentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response

ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. ACR70 Responder is a participant who has at least 70% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.

Time frame:
Week 12 and Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
Percentage of ParticipantsPlaceboBaricitinib 2 mgBaricitinib 4 mg
Week 122.312.611.3
Week 243.413.216.9
Statistical analysis
  • Placebo vs Baricitinib 4 mg · Regression, Logistic · p = 0.002 (a priori p-value significance threshold: 2-sided ≤0.05)If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
  • Placebo vs Baricitinib 2 mg · Regression, Logistic · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
  • Placebo vs Baricitinib 4 mg · Regression, Logistic · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
  • Placebo vs Baricitinib 2 mg · Regression, Logistic · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
SecondaryChange From Baseline in DAS28 - Erythrocyte Sedimentation Rate (ESR)

DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

Time frame:
Baseline, Week 12
Reported as:
Mean · Units on a Scale
Change From Baseline in DAS28 - Erythrocyte Sedimentation Rate (ESR)
Units on a ScalePlaceboBaricitinib 2 mgBaricitinib 4 mg
Change From Baseline in DAS28 - Erythrocyte Sedimentation Rate (ESR)-0.92 ± 1.21-1.52 ± 1.37-1.80 ± 1.44
Statistical analysis
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
SecondaryChange From Baseline in Clinical Disease Activity Index Score

The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

Time frame:
Baseline, Week 24
Reported as:
Mean · Units on a Scale
Change From Baseline in Clinical Disease Activity Index Score
Units on a ScalePlaceboBaricitinib 2 mgBaricitinib 4 mg
Change From Baseline in Clinical Disease Activity Index Score-12.19 ± 16.96-17.17 ± 16.96-20.30 ± 16.29
Statistical analysis
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.009 (a priori p-value significance threshold: 2-sided ≤0.05)
SecondaryChange From Baseline in Measures of SDAI Score

The SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 24
Reported as:
Mean · Units on a Scale
Change From Baseline in Measures of SDAI Score
Units on a ScalePlaceboBaricitinib 2 mgBaricitinib 4 mg
Change From Baseline in Measures of SDAI Score-12.07 ± 17.50-17.80 ± 17.50-21.26 ± 17.01
Statistical analysis
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.003 (a priori p-value significance threshold: 2-sided ≤0.05)
SecondaryPercentage of Participants Achieving ACR/EULAR Remission - Boolean Remission

The ACR/EULAR definitions of RA remission includes a Boolean-based definition. The Boolean-based definition of remission occurs when all 4 of the following criteria are met at the same visit: TJC28 ≤1, SJC28 ≤1, acute phase response using C-reactive protein (milligrams per deciliter) ≤1, Patient's Global Assessment of Disease Activity using VAS (cm) ≤1.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ACR/EULAR Remission - Boolean Remission
Percentage of ParticipantsPlaceboBaricitinib 2 mgBaricitinib 4 mg
Percentage of Participants Achieving ACR/EULAR Remission - Boolean Remission1.14.06.8
Statistical analysis
  • Placebo vs Baricitinib 4 mg · Regression, Logistic · p = 0.012 (a priori p-value significance threshold: 2-sided ≤0.05)If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
  • Placebo vs Baricitinib 2 mg · Regression, Logistic · p = 0.104 (a priori p-value significance threshold: 2-sided ≤0.05)If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.
SecondaryChange From Baseline in Duration of Participant Reported Outcome - Morning Joint Stiffness

Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on that day. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

Time frame:
Baseline, Week 24
Reported as:
Median · Minutes
Change From Baseline in Duration of Participant Reported Outcome - Morning Joint Stiffness
MinutesPlaceboBaricitinib 2 mgBaricitinib 4 mg
Change From Baseline in Duration of Participant Reported Outcome - Morning Joint Stiffness-8.0 (-15.0 to 0.0)-25.5 (-40.0 to -15.0)-27.0 (-40.0 to -15.0)
Statistical analysis
  • Placebo vs Baricitinib 4 mg · Wilcoxon (Mann-Whitney) · p = 0.002 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 2 mg · Wilcoxon (Mann-Whitney) · p = 0.004 (a priori p-value significance threshold: 2-sided ≤0.05)
SecondaryChange From Baseline in Worst Tiredness Numeric Rating Scale (NRS)

A participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing (no tiredness) and 10 representing (as bad as you can imagine). Participants rate their tiredness by selecting the one number that describes their worst level of tiredness during the past 24 hours. Total scores ranged from 0-10.

Time frame:
Baseline, Week 24
Reported as:
Mean · Units on a Scale
Change From Baseline in Worst Tiredness Numeric Rating Scale (NRS)
Units on a ScalePlaceboBaricitinib 2 mgBaricitinib 4 mg
Change From Baseline in Worst Tiredness Numeric Rating Scale (NRS)-1.1 ± 2.3-1.8 ± 2.7-2.0 ± 2.6
Statistical analysis
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.018 (a priori p-value significance threshold: 2-sided ≤0.05)
SecondaryChange From Baseline in Worst Joint Pain NRS

Participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing (no joint pain) and 10 representing (pain as bad as you can imagine). Participants rate their joint pain by selecting the one number that describes their worst level of joint pain during the past 24 hours. Total scores ranged from 0-10.

Time frame:
Baseline, Week 24
Reported as:
Mean · Units on a Scale
Change From Baseline in Worst Joint Pain NRS
Units on a ScalePlaceboBaricitinib 2 mgBaricitinib 4 mg
Change From Baseline in Worst Joint Pain NRS-1.2 ± 2.4-2.1 ± 2.5-2.5 ± 2.7
Statistical analysis
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale Scores

The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 (Not at all) to 4 (Very much) for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · Units on a Scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale Scores
Units on a ScalePlaceboBaricitinib 2 mgBaricitinib 4 mg
Week 125.9 ± 10.58.8 ± 10.08.5 ± 9.9
Week 246.6 ± 10.78.8 ± 10.49.7 ± 10.7
Statistical analysis
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.005 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.004 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.002 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.026 (a priori p-value significance threshold: 2-sided ≤0.05)
SecondaryChange From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)

The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · Units on a Scale
Change From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)
Units on a ScalePlaceboBaricitinib 2 mgBaricitinib 4 mg
Week 12 MCS1.6 ± 10.73.4 ± 9.72.4 ± 10.0
Week 24 MCS2.5 ± 10.83.2 ± 11.53.3 ± 10.6
Week 12 PCS3.3 ± 8.06.3 ± 8.86.4 ± 8.8
Week 24 PCS2.4 ± 8.26.4 ± 8.97.0 ± 9.3
Statistical analysis
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.448
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.058
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.446
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.401
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.001
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.001
SecondaryChange From Baseline in European Quality of Life-5 Dimensions-5 Level Scores

European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · Units on a Scale
Change From Baseline in European Quality of Life-5 Dimensions-5 Level Scores
Units on a ScalePlaceboBaricitinib 2 mgBaricitinib 4 mg
Index Score (US Algorithm) Wk 12 (N=168,168,173)0.035 ± 0.1670.080 ± 0.1520.128 ± 0.148
Index Score (US Algorithm) Wk 24 (N=167,168,173)0.042 ± 0.1660.082 ± 0.1700.128 ± 0.157
Index Score (UK Algorithm) Wk 12 (N=168,168,173)0.052 ± 0.2500.116 ± 0.2240.191 ± 0.224
Index Score (UK Algorithm) Wk 24 (N=167,168,173)0.064 ± 0.2450.122 ± 0.2500.192 ± 0.237
Self-Perceived Health Wk 12 (N=168,168,173)4.1 ± 29.014.1 ± 24.210.3 ± 27.3
Self-Perceived Health Wk 24 (N=167,168,173)3.8 ± 27.811.4 ± 26.513.3 ± 29.0
Statistical analysis
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.003 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001 (a priori p-value significance threshold: 2-sided ≤0.05)
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.002 (a priori p-value significance threshold: 2-sided ≤0.05)
SecondaryPercentage Change From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Scores

The WPAI-RA participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. Using 6 questions, it yields four types of scores: absenteeism (work time missed), presenteeism (impairment at work), work productivity loss (overall work impairment), and activity impairment, with outcomes expressed as impairment percentages. Percentage work time missed absenteeism: Q2/(Q2+Q4)\*100, Percentage impairment while working presenteeism: Q5/10\*100; Percentage overall work impairment work productivity loss: Q2/(Q2+Q4)+\[(1-Q2/(Q2+Q4))x(Q5/10)\]\*100; Percentage activity impairment activity impairment: Q6/10\*100. Higher numbers indicate greater impairment and less productivity, that is, worse outcomes.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · Percentage of Impairment
Percentage Change From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Scores
Percentage of ImpairmentPlaceboBaricitinib 2 mgBaricitinib 4 mg
Absenteeism Week 123.2 ± 23.8-6.7 ± 26.6-6.5 ± 22.1
Absenteeism Week 240.9 ± 12.4-1.9 ± 31.4-2.3 ± 29.5
Presenteeism Week 12-4.1 ± 26.4-12.0 ± 24.0-10.5 ± 24.0
Presenteeism Week 24-7.1 ± 30.5-11.4 ± 24.9-15.6 ± 25.4
Work Productivity Loss Week 12-4.2 ± 27.8-13.7 ± 26.7-12.3 ± 24.8
Work Productivity Loss Week 24-6.0 ± 33.4-13.2 ± 27.6-14.8 ± 32.4
Activity Impairment Week 12-10.4 ± 22.8-16.0 ± 25.5-18.1 ± 24.8
Activity Impairment Week 24-15.7 ± 25.5-20.8 ± 23.7-25.8 ± 25.2
Statistical analysis
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.362
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.170
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.753
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.715
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.077
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.058
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.232
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.534
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.079
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.070
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.327
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.479
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.005
  • Placebo vs Baricitinib 4 mg · ANCOVA · p = 0.001
  • Placebo vs Baricitinib 2 mg · ANCOVA · p = 0.030
SecondaryPopulation Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib
Time frame:
Week 0 (Baseline): 15 min. post-dose, 1 hour post-dose. Week 4 (Day 28 ±2 days): 2 to 4 hours post-dose. Week 8 (Day 56 ±3 days): 4 to 6 hours post-dose. Week 12 (Day 84 ±3 days): Pre-dose. Week 24 (Day 168 ±5 days): Pre-dose.
Reported as:
Geometric mean · nanomoles/Liter (nmol/L)
Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib
nanomoles/Liter (nmol/L)Baricitinib 2 mgBaricitinib 4 mg
Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib65.6 ± 21.4130 ± 19.3
SecondaryPopulation PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib
Time frame:
Week 0 (Baseline): 15 min. post-dose, 1 hour post-dose. Week 4 (Day 28 ±2 days): 2 to 4 hours post-dose. Week 8 (Day 56 ±3 days): 4 to 6 hours post-dose. Week 12 (Day 84 ±3 days): Pre-dose. Week 24 (Day 168 ±5 days): Pre-dose.
Reported as:
Geometric mean · nanomoles*hour/Liter (nmol*h/L)
Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib
nanomoles*hour/Liter (nmol*h/L)Baricitinib 2 mgBaricitinib 4 mg
Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib615 ± 43.11140 ± 38.7

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo -Treatment Period—14/176 (8%)79/176 (44.9%)
Baricitinib 2 mg - Treatment Period—8/174 (4.6%)105/174 (60.3%)
Baricitinib 4 mg - Treatment Period—19/177 (10.7%)102/177 (57.6%)
Rescue Period—2/127 (1.6%)6/127 (4.7%)
Placebo - Follow Up Period—1/19 (5.3%)2/19 (10.5%)
Baricitinib 2 mg - Follow Up Period—1/9 (11.1%)4/9 (44.4%)
Baricitinib 4 mg - Follow Up Period—0/20 (0%)1/20 (5%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventPlacebo -Treatment PeriodBaricitinib 2 mg - Treatment PeriodBaricitinib 4 mg - Treatment PeriodRescue PeriodPlacebo - Follow Up PeriodBaricitinib 2 mg - Follow Up PeriodBaricitinib 4 mg - Follow Up Period
Diverticulum intestinal haemorrhagicGastrointestinal disorders0/1760/1740/1770/1270/191/90/20
CellulitisInfections and infestations2/1760/1740/1770/1271/190/90/20
Rheumatoid arthritisMusculoskeletal and connective tissue disorders3/1760/1742/1771/1270/190/90/20
HypertensionVascular disorders2/1760/1740/1770/1270/190/90/20
Coronary artery diseaseCardiac disorders0/1760/1742/1770/1270/190/90/20
Urinary tract infectionInfections and infestations0/1760/1742/1770/1270/190/90/20
Muscle ruptureInjury, poisoning and procedural complications0/1760/1740/1771/1270/190/90/20
Carpal tunnel syndromeNervous system disorders1/1761/1740/1771/1270/190/90/20
Vulval abscessInfections and infestations0/1450/1371/1490/1130/160/90/18
Oral disorderGastrointestinal disorders0/1761/1740/1770/1270/190/90/20
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPlacebo -Treatment PeriodBaricitinib 2 mg - Treatment PeriodBaricitinib 4 mg - Treatment PeriodRescue PeriodPlacebo - Follow Up PeriodBaricitinib 2 mg - Follow Up PeriodBaricitinib 4 mg - Follow Up Period
LymphopeniaBlood and lymphatic system disorders0/1760/1740/1770/1270/191/90/20
CellulitisInfections and infestations0/1760/1740/1770/1270/191/90/20
InsomniaPsychiatric disorders0/1760/1740/1770/1270/191/90/20
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/1765/1745/1770/1270/191/90/20
HeadacheNervous system disorders11/17617/17412/1773/1270/190/90/20
Upper respiratory tract infectionInfections and infestations8/17615/1749/1770/1270/190/90/20
NasopharyngitisInfections and infestations7/17612/1749/1774/1271/190/90/20
DiarrhoeaGastrointestinal disorders12/17610/1747/1770/1270/190/90/20
NauseaGastrointestinal disorders5/1767/17410/1770/1270/190/90/20
BronchitisInfections and infestations6/1766/17410/1770/1270/190/90/20

Baseline characteristics

Modified Intent-to-Treat (mITT) population includes all randomized participants who received at least 1 dose of the study drug.

Age, Continuous
Age, Continuous(Years)PlaceboBaricitinib 2 mgBaricitinib 4 mgTotal
Mean56.0 ± 10.755.1 ± 11.155.9 ± 11.355.7 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBaricitinib 2 mgBaricitinib 4 mgTotal
Female145137149431
Male31372896
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBaricitinib 2 mgBaricitinib 4 mgTotal
American Indian or Alaska Native9121132
Asian1191232
Native Hawaiian or Other Pacific Islander0000
Black or African American89724
White147144144435
More than one race1001
Unknown or Not Reported0033
Region of Enrollment
Region of Enrollment(Participants)PlaceboBaricitinib 2 mgBaricitinib 4 mgTotal
Argentina95721
Australia89421
Austria53816
Belgium1113
Canada1438
Denmark2316
France710724
Germany85619
Greece4329
Israel981330
Italy2338
Japan66820
Mexico9121031
Netherlands0112
Poland1013932
South Korea43310
Spain1071027
Switzerland1247
Turkey1113
United Kingdom2114
United States777475226
Duration of Rheumatoid Arthritis
Duration of Rheumatoid Arthritis(Years)PlaceboBaricitinib 2 mgBaricitinib 4 mgTotal
Mean14.0 ± 9.613.7 ± 8.014.3 ± 9.414.0 ± 9.0
Tender Joint Count of 68 Evaluable Joints
Tender Joint Count of 68 Evaluable Joints(Number of Joints)PlaceboBaricitinib 2 mgBaricitinib 4 mgTotal
Mean28.3 ± 16.431.0 ± 16.328.1 ± 15.629.1 ± 16.1
Swollen Joint Count of 66 Evaluable Joints
Swollen Joint Count of 66 Evaluable Joints(Number of Joints)PlaceboBaricitinib 2 mgBaricitinib 4 mgTotal
Mean17.2 ± 10.818.6 ± 12.316.3 ± 8.917.4 ± 10.8
High Sensitivity C-Reactive Protein (hsCRP)
High Sensitivity C-Reactive Protein (hsCRP)(milligrams/liter (mg/L))PlaceboBaricitinib 2 mgBaricitinib 4 mgTotal
Mean20.64 ± 25.2619.87 ± 22.4819.76 ± 24.8420.09 ± 24.19
08

Study locations

103 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Glendale, Arizona 85304, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Phoenix, Arizona 85023, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tucson, Arizona 85724, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palo Alto, California 94304, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Upland, California 91786, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Danbury, Connecticut 06810, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Trumbull, Connecticut 06611, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lewes, Delaware 19958, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boynton Beach, Florida 33472, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32806, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tamarac, Florida 33321, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampa, Florida 33613, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boise, Idaho 83702, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46260, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lansing, Michigan 48910, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Louis, Missouri 63117, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Freehold, New Jersey 07728, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albany, New York 12206, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hartsdale, New York 10530, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rochester, New York 14618, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oklahoma City, Oklahoma 73103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tulsa, Oklahoma 74135, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bethlehem, Pennsylvania 18017, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania 19152, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wyomissing, Pennsylvania 19610, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Myrtle Beach, South Carolina 29572, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nassau Bay, Texas 77058, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Webster, Texas 77508, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chesapeake, Virginia 23320, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kennewick, Washington 99336, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vancouver, Washington 98664, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Franklin, Wisconsin 53132, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, C1015ABO, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosario, 2000, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Miguel De Tucuman, T4000AXL, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kogarah, New South Wales 04266-010, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Maroochydore, Queensland 4558, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fitzroy, Victoria 3065, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Graz, 8036, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vienna, 1100, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussels, 1000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mons, 7000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toronto, Ontario M5T 3L9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frederiksberg, 2000, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Glostrup, 2600, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Odense, 5000, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montpellier, 34295, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orleans, 45032, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75679, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rennes, 35056, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tours, 3700, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dresden, 01067, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 22081, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heidelberg, 69120, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Würzburg, 97080, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, 11527, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heraklion, 71110, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kifissia, 14561, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Larissa, 411 10, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ashkelon, 78278, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beer Yaakov, 70300, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Haifa, 34362, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jerusalem, 91120, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kfar Saba, 44281, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Petah Tikva, 49100, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tel Aviv, 64239, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Firenze, 50134, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pisa, 56100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rome, 00100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 284-0003, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 810-8563, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hiroshima, 730-0017, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hokkaido, 060-8648, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Japan, 275-8580, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kagawa, 761-0793, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kumamoto, 861-1196, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagasaki, 856-8562, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okayama, 700-8607, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saitama, 359-1111, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 104-8560, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 110-744, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44650, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 06090, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64040, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Luis Potosi, 78213, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ubbergen, 6574 NA, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdansk, 80-546, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nadarzyn, 05-830, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 02-507, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Caguas, 00725, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00927, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santurce, 00909, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Vila Joiosa, 03570, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santander, 39008, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46026, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fribourg, 1708, Switzerland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lausanne, CH-1011, Switzerland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zürich, 8091, Switzerland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edirne, 22030, Turkey

Showing the first 100 of 103 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, Winthrop KL. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022 Mar;81(3):335-343. doi: 10.1136/annrheumdis-2021-221276. Epub 2021 Oct 27. PubMed 34706874 ↗
  • Wells AF, Jia B, Xie L, Valenzuela GJ, Keystone EC, Li Z, Quebe AK, Griffing K, Otawa S, Haraoui B. Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study. Rheumatol Ther. 2021 Jun;8(2):987-1001. doi: 10.1007/s40744-021-00317-9. Epub 2021 May 24. PubMed 34028703 ↗
  • Emery P, Tanaka Y, Cardillo T, Schlichting D, Rooney T, Beattie S, Helt C, Smolen JS. Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. Arthritis Res Ther. 2020 May 15;22(1):115. doi: 10.1186/s13075-020-02199-8. Erratum In: Arthritis Res Ther. 2020 Jul 2;22(1):166. doi: 10.1186/s13075-020-02257-1. PubMed 32414425 ↗
  • Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Riddle Camp J, Cardillo TE, Ishii T, Winthrop KL. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361. Epub 2018 Sep 15. Erratum In: J Rheumatol. 2019 Dec;46(12):1648-1649. doi: 10.3899/jrheum.171361.C1. PubMed 30219772 ↗
  • Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP, Schlichting DE, Zuckerman SH, Emery P. Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis. Arthritis Rheumatol. 2018 Dec;70(12):1923-1932. doi: 10.1002/art.40680. Epub 2018 Oct 22. PubMed 30058112 ↗
  • Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20. PubMed 29463520 ↗
  • Genovese MC, Kremer JM, Kartman CE, Schlichting DE, Xie L, Carmack T, Pantojas C, Sanchez Burson J, Tony HP, Macias WL, Rooney TP, Smolen JS. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology (Oxford). 2018 May 1;57(5):900-908. doi: 10.1093/rheumatology/kex489. PubMed 29415145 ↗
  • Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, Stoykov I, Rooney T, Bird P, Sanchez Burson JM, Genovese MC, Combe B. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis. 2017 Apr;76(4):694-700. doi: 10.1136/annrheumdis-2016-209821. Epub 2016 Oct 31. PubMed 27799159 ↗
  • Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS. Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247. PubMed 27028914 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Jun 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 3 years 7 months after primary completion. A results delay was requested in Sep 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2012
First posted
Nov 2, 2012
Start
Jan 2013
Primary completionActual
Jun 2014
CompletionActual
Sep 2014
Results delay requested
Sep 29, 2014
Results first posted
Jan 18, 2018
Last update
Sep 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01721044
Responsible party
Sponsor
First posted
Nov 2, 2012
Start date
Jan 2013
Primary completion
Jun 2014
Completion
Sep 2014
Results posted
Jan 18, 2018
Last update
Sep 18, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion